COMMUNIQUÉS West-GlobeNewswire

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
17/09/2025
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong [...]
MyCardiologist Launches Immediate Care Clinic, Offering Same-Day Access to Expert Cardiac Care
17/09/2025
MyCardiologistNow provides a new walk-in clinic for patients needing prompt evaluation of non-life-threatening heart symptoms MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- MyCardiologist , one of South Florida’s leading [...]
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
17/09/2025
New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin types New data show improved quality of life and decreased impact on families for [...]
ALK and GenSci partner to expand the AIT market in China
17/09/2025
Inside Information GenSci is granted exclusive rights to ALK’s house dust mite AIT products in China. ALK will be eligible for upfront and milestone payments of up to DKK 1.3 billion in addition to income from supplying [...]
Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease
17/09/2025
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative treatment for patients on peritoneal dialysis (PD), today [...]
Oruka Therapeutics Announces $180 Million Private Placement
17/09/2025
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the [...]
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
17/09/2025
Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions [...]
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune Diseases
17/09/2025
Positive safety and tolerability profile of NAV-240 in Phase 1a study support further development Phase 1b study fully enrolled and data expected in early 2026 Further clinical development of NAV-240 to begin in early [...]
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
17/09/2025
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in [...]
Communiqué de presse : EADV : Les résultats de l’étude de phase 2a montrent que le brivekimig de Sanofi est efficace dans le traitement de l’hidrosadénite suppurée
17/09/2025
EADV : Les résultats de l’étude de phase 2a montrent que le brivekimig de Sanofi est efficace dans le traitement de l’hidrosadénite suppurée Dans l’étude de phase 2a, le brivekimig a entraîné des améliorations [...]
New Life Expands Prestige Recovery Services To The Middle East
17/09/2025
MARBELLA, Spain, Sept. 17, 2025 (GLOBE NEWSWIRE) -- New Life announces expansion of its luxury wellness and recovery services to Dubai and Abu Dhabi through a strategic partnership with Aims Healthcare. New Life Expands [...]
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
17/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75 [...]
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
17/09/2025
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapies Cancer Research UK’s Centre for Drug [...]
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
16/09/2025
MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“ Theratechnologies ” or the “ Company ”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has [...]
Theratechnologies reçoit l’approbation définitive du tribunal relativement au plan d’arrangement proposé visant son acquisition par Future Pak
16/09/2025
MONTRÉAL, 16 sept. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade de la commercialisation, a annoncé aujourd’ [...]
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser
16/09/2025
WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has completed a U.S. Food and Drug Administration (“FDA”) 510(k) clearance [...]
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
16/09/2025
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress [...]
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
16/09/2025
Secures Incentive Offer of up to US$255K to Establish Operations in Indianapolis TORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90 [...]
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
16/09/2025
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of [...]

Pages